This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
AISF position paper on HCV in immunocompromised patients
Toniutto P.;Pirisi M.;
2019-01-01
Abstract
This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
DLD AISF position paper.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non pubblico
Dimensione
483.97 kB
Formato
Adobe PDF
|
483.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
